Viking Global Investors LP and affiliated reporting persons filed a Schedule 13G with the SEC on October 26, 2026, disclosing beneficial ownership of shares in City Therapeutics, Inc. as of the event date of October 19, 2026.

Key Highlights

  • Lead filer: Viking Global Investors LP, a Delaware limited partnership, is the primary reporting entity among ten reporting persons named in the filing.
  • Aggregate ownership: Viking Global Investors LP and individual reporting persons O. Andreas Halvorsen and Rose S. Shabet each report beneficial ownership of 3,727,005 shares, representing 7% of the class.
  • Voting and dispositive power: All 3,727,005 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Sub-position: Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities GP LLC, and Viking Global Opportunities Portfolio GP LLC each report 2,608,904 shares, representing 4.9% of the class.
  • Vintage IV position: Viking Global Opportunities Vintage IV (Aggregator) LP and its affiliated GP entities each report 1,118,101 shares, representing 2.1% of the class.
  • Triggering event: The date of the event requiring this filing is stated as October 19, 2026.

Viking Global's Disclosed Position in City Therapeutics Common Stock

According to the filing, ten reporting persons collectively submitted a single Schedule 13G covering City Therapeutics, Inc. (CUSIP 178782108), whose common stock has a par value of $0.0001 per share. The issuer's principal executive offices are listed at 399 Binney Street, Cambridge, Massachusetts 02142. The filing discloses that the business address for all reporting persons is 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.

The filing identifies Viking Global Investors LP as the top-level reporting entity, with O. Andreas Halvorsen, a citizen of Norway, and Rose S. Shabet, a citizen of the United States, also named as individual reporting persons. Each of these three parties reports beneficial ownership of 3,727,005 shares, all held with shared voting and shared dispositive power and none held with sole voting or sole dispositive power. That figure represents 7% of the class, according to the filing.

Within the broader structure, Viking Global Opportunities Illiquid Investments Sub-Master LP, organized in the Cayman Islands, along with its associated Delaware-organized GP entities, reports 2,608,904 shares at 4.9% of the class. A separate sub-structure, Viking Global Opportunities Vintage IV (Aggregator) LP, also Cayman Islands-organized, together with its Delaware GP entities, reports 1,118,101 shares at 2.1% of the class. In each case, the filing reflects shared voting and shared dispositive power with no sole authority over the shares.

What Was Disclosed

The Schedule 13G filed October 26, 2026 discloses that Viking Global Investors LP and nine affiliated entities and individuals beneficially own shares of City Therapeutics, Inc. common stock, with the top-level position of 3,727,005 shares representing 7% of the class as of October 19, 2026.